Ph.D., Program Director, MTRAC for Life Sciences Commercialization
Brad comes to the MTRAC team with 15-plus years of experience in the development of drugs and biologics, and particular expertise in preclinical development and translational research in the field of cardiovascular physiology and regenerative medicine. Much of his career has focused on the development of stem cell therapies for the treatment of myocardial infarction and heart failure. He has considerable experience in leading cross-functional project teams, and has transitioned therapies from product concept through preclinical development, IND approval and eventual clinical trial. Prior to leading MTRAC, Brad served as a Mentor in Residence for the U-M Tech Transfer Office, was the Director of Product Development at Aastrom Biosciences, and the Director of Cardiac Research at Osiris Therapeutics Inc. He also spent several years as a Principal Scientist with Pfizer’s Esperion Division, studying the anti-atherosclerotic properties of ApoA-I Milano, and other novel peptides. He received in Ph.D. in Physiology in 1993 from the University of Michigan, and completed post-doctoral fellowships in the departments of Cardiothoracic Surgery and Physiology at the University of Wisconsin.